Brandon Essink, MD, CPI, is the lead author of study results exploring a next-generation flu vaccine for adults 50+. The published results highlight the potential for combining cell-based approaches and adjuvants to enhance immunogenicity relative to standard flu vaccines on the market.
Title: “A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older.”
Link: https://www.sciencedirect.com/science/article/pii/S0264410X2500088X
